Orthofix Medical Inc. logo

Orthofix Medical Inc.

OFIX

NASDAQHealthcareMedical - Devices

Regular session

$9.9056

−$0.1044 · -1.04%

Aug 24, 11:17 AM ET

OFIX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

64

Undervalued

Momentum

42

Neutral

Sentiment

68

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Massimo Calafiore
Listed since
Apr 24, 1992
Employees
1,605

Market position

Day range

Current $9.9056

52-week range

Current $9.9056

Open
$10.05
Previous close
$10.01
Volume
45.03K
0.11× average
Average volume
395.37K
Average daily volume
Market cap
400.4M USD
Beta
0.67
Market reference 1
50-day average
$10.6046
-6.59% below average
200-day average
$12.5624
-21.15% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
751.86M USD
P/E (TTM)
-6.45×
P/B (TTM)
0.94×
P/S (TTM)
0.48×
EV / EBITDA
-33.64×
Earnings yield
-15.25%
Free cash flow yield
-0.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
69.59%
Operating margin
-3.05%
Net margin
-7.41%
Return on equity
-20.49%
Return on assets
-10.84%
Return on invested capital
-10.01%

Financial health

Debt / equity
0.55×
Current ratio
2.45×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends85%47%8%-30%Gross margin, FY2021: 75.26%Gross margin, FY2022: 73.18%Gross margin, FY2023: 65.13%Gross margin, FY2024: 68.28%Gross margin, FY2025: 67.09%Operating margin, FY2021: -1.79%Operating margin, FY2022: -2.88%Operating margin, FY2023: -18.63%Operating margin, FY2024: -10.58%Operating margin, FY2025: -8.33%Net margin, FY2021: -8.26%Net margin, FY2022: -4.29%Net margin, FY2023: -20.28%Net margin, FY2024: -15.76%Net margin, FY2025: -11.21%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 75.26%. Gross margin FY2022 73.18%. Gross margin FY2023 65.13%. Gross margin FY2024 68.28%. Gross margin FY2025 67.09%. Operating margin FY2021 -1.79%. Operating margin FY2022 -2.88%. Operating margin FY2023 -18.63%. Operating margin FY2024 -10.58%. Operating margin FY2025 -8.33%. Net margin FY2021 -8.26%. Net margin FY2022 -4.29%. Net margin FY2023 -20.28%. Net margin FY2024 -15.76%. Net margin FY2025 -11.21%.

Income trends

Revenue

822.31M USD+2.85%

Operating income

−68.47M USD+19.08%

Net income

−92.19M USD+26.83%
Income trends across reported periods919.68M USD530.2M USD140.72M USD−248.77M USDRevenue, FY2021: 464.48M USDRevenue, FY2022: 460.71M USDRevenue, FY2023: 746.64M USDRevenue, FY2024: 799.49M USDRevenue, FY2025: 822.31M USDOperating income, FY2021: −8.32M USDOperating income, FY2022: −13.27M USDOperating income, FY2023: −139.11M USDOperating income, FY2024: −84.62M USDOperating income, FY2025: −68.47M USDNet income, FY2021: −38.38M USDNet income, FY2022: −19.75M USDNet income, FY2023: −151.4M USDNet income, FY2024: −126M USDNet income, FY2025: −92.19M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 464.48M USD. Revenue FY2022 460.71M USD. Revenue FY2023 746.64M USD. Revenue FY2024 799.49M USD. Revenue FY2025 822.31M USD. Operating income FY2021 −8.32M USD. Operating income FY2022 −13.27M USD. Operating income FY2023 −139.11M USD. Operating income FY2024 −84.62M USD. Operating income FY2025 −68.47M USD. Net income FY2021 −38.38M USD. Net income FY2022 −19.75M USD. Net income FY2023 −151.4M USD. Net income FY2024 −126M USD. Net income FY2025 −92.19M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue822.31M USD799.49M USD746.64M USD460.71M USD464.48M USD
Cost of goods sold270.61M USD253.61M USD260.37M USD123.54M USD114.91M USD
Gross profit551.71M USD545.89M USD486.27M USD337.17M USD349.57M USD
Research and development57.11M USD73.64M USD80.23M USD49.07M USD49.62M USD
Selling, general, and administrative456.39M USD532.53M USD530.4M USD308.78M USD290.67M USD
Operating expenses620.18M USD630.5M USD625.38M USD350.44M USD357.88M USD
Interest expense17.49M USD29.63M USD8.63M USD1.29M USD1.84M USD
Depreciation and amortization50.97M USD60.06M USD60.56M USD32.08M USD33.1M USD
Operating income−68.47M USD−84.62M USD−139.11M USD−13.27M USD−8.32M USD
Net income−92.19M USD−126M USD−151.4M USD−19.75M USD−38.38M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-282.61%
11 comparable reports
Latest EPS result
-0.39
Estimate -0.41 · Beat by 4.85%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.24-0.33-0.9-1.47Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -0.75, estimate 0.03, surprise -2600.00%, Miss. Q2 2025, reported May 6, 2025: actual -1.35, estimate -0.38, surprise -255.26%, Miss. Q3 2025, reported Aug 5, 2025: actual -0.36, estimate -0.44, surprise +18.18%, Beat. Q4 2025, reported Nov 4, 2025: actual -0.57, estimate 0.12, surprise -575.00%, Miss. Q1 2026, reported Feb 24, 2026: actual -0.056, estimate -0.19, surprise +70.79%, Beat. Q2 2026, reported May 5, 2026: actual -0.52, estimate -0.68, surprise +23.53%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.39, estimate -0.41, surprise +4.85%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates228.71M213.24M197.77M182.3MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 215.7M USD, estimate 212.72M USD, surprise +1.40%, Beat. Q2 2025, reported May 6, 2025: actual 193.65M USD, estimate 191.09M USD, surprise +1.34%, Beat. Q3 2025, reported Aug 5, 2025: actual 200.7M USD, estimate 196.19M USD, surprise +2.30%, Beat. Q4 2025, reported Nov 4, 2025: actual 205.63M USD, estimate 199.99M USD, surprise +2.82%, Beat. Q1 2026, reported Feb 24, 2026: actual 219.91M USD, estimate 218.7M USD, surprise +0.56%, Beat. Q2 2026, reported May 5, 2026: actual 196.71M USD, estimate 196.4M USD, surprise +0.16%, Beat. Q3 2026, reported Aug 5, 2026: actual 210.93M USD, estimate 209.28M USD, surprise +0.79%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 210.7M USD, surprise —, Comparison unavailable.

OFIX news

OFIX peers

ETFs holding OFIX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research OFIX

research.disclaimer